Features of Thyroid Pathology in Patients with Down Syndrome
https://doi.org/10.31550/1727-2378-2024-23-6-77-80
Abstract
Aim. To demonstrate the prevalence and structure of thyroid diseases in children with Down syndrome (DS), and to analyze the features of their diagnosis and treatment.
Key points. Thyroid gland pathology in DS includes congenital hypothyroidism (CH), subclinical hypothyroidism (SH), chronic autoimmune thyroiditis (CAT), and diffuse toxic goiter (DTG). Thyroid diseases are more common and occur earlier in individuals with DS than in the general population; their presence is independent of gender. SH is identified in 7–40% of patients with DS, but progresses to overt hypothyroidism in less than half of the cases. Various clinical guidelines recommend that patients with DS should have their thyroid-stimulating hormone (TSH) levels monitored regularly, every 6–12 months, and, if necessary, their free thyroxine and thyroid peroxidase antibodies. The treatment of CH, CAT, and DTG in DS patients is the same as in patients without DS. Most researchers advocate against levothyroxine therapy for SH, as there is no evidence of benefit from early treatment, and elevated TSH levels are often mild and transient.
Conclusion. The high prevalence and wide spectrum of thyroid pathology in patients with DS necessitate regular monitoring of hormone levels. The complexity of interpreting isolated TSH elevation can complicate treatment decisions. In recent years, a more justified strategy of “watchful waiting” along with more frequent laboratory tests has become more prevalent.
About the Authors
A. D. Gudis
I.M. Sechenov First Moscow State Medical University (Sechenov University)
Russian Federation
Russian Federation
19 Bolshaya Pirogovskaya, build. 2, Moscow, 119435
A. V. Vitebskaya
I.M. Sechenov First Moscow State Medical University (Sechenov University)
Russian Federation
Russian Federation
19 Bolshaya Pirogovskaya, build. 2, Moscow, 119435
References
1. Zaman S., Fortea J. The crucial history of Down syndrome. Lancet Neurol. 2022;21(3):222. DOI: 10.1016/S1474-4422(22)00047-32
2. Dimopoulos K., Constantine A., Clift P., Condliffe R. et al. Cardiovascular complications of Down syndrome: scoping review and expert consensus. Circulation. 2023;147(5):425–41 DOI: 10.1161/CIRCULATIONAHA.122.059706
3. Szeliga K., Antosz A., Skrzynska K., Kalina-Faska B. et al. Subclinical hypothyroidism as the most common thyroid dysfunction status in children with Down's syndrome. Front. Endocrinol. 2022;12:782865. DOI: 10.3389/fendo.2021.782865
4. Feldman P.M., Rodriguez N., Morrison E., Barton B. et al. Prospective study of thyroid function in the first year of life in infants with Down syndrome. Eur. J. Pediatr. 2023;182(6):2903–11. DOI: 10.1007/s00431-023-04954-w
5. Tüysüz B., Beker D.B. Thyroid dysfunction in children with Down's syndrome. Acta Paediatr. 2001;90(12):1389–93. DOI: 10.1080/08035250152708770
6. Metwalley K.A., Farghaly H.S. Endocrinal dysfunction in children with Down syndrome. Ann. Pediatr. Endocrinol. Metab. 2022;27(1):15–21. DOI: 10.6065/apem.2142236.118
7. Kaplowitz P.B. Neonatal thyroid disease: testing and management. Pediatr. Clin. North Am. 2019;66(2):343–52. DOI: 10.1016/j.pcl.2018.12.005
8. AlAaraj N., Soliman A.T., Itani M., Khalil A. et al. Prevalence of thyroid dysfunctions in infants and children with Down Syndrome (DS) and the effect of thyroxine treatment on linear growth and weight gain in treated subjects versus DS subjects with normal thyroid function: a controlled study. Acta Biomed. 2019;90(8-S):36–42. DOI: 10.23750/abm.v90i8-S.8503
9. Aversa T., Corica D., Zirilli G., Pajno G.B. et al. Phenotypic expression of autoimmunity in children with autoimmune thyroid disorders. Front. Endocrinol. 2019;10:476. DOI: 10.3389/fendo.2019.00476
10. Molinari S., Fossati C., Nicolosi M.L., Di Marco S. et al. Endocrine, auxological and metabolic profile in children and adolescents with Down syndrome: from infancy to the first steps into adult life. Front. Endocrinol. 2024;15:1348397. DOI: 10.3389/fendo.2024.1348397
11. Sanyal D., Bhattacharjee K. High thyroid-stimulating hormone level in Down's syndrome: a mere resetting of hypothalamopituitary axis in subclinical hypothyroidism? Indian J. Endocrinol. Metab. 2020;24(5):406–9. DOI: 10.4103/ijem.IJEM_422_20
12. Noble S.E., Leyland K., Findlay C.A., Clark C.E. et al. School based screening for hypothyroidism in Down's syndrome by dried blood spot TSH measurement. Arch. Dis. Child. 2000;82(1):27–31. DOI: 10.1136/adc.82.1.27
13. Söderbergh A., Gustafsson J., Ekwall O., Hallgren A. et al. Autoantibodies linked to autoimmune polyendocrine syndrome type I are prevalent in Down syndrome. Acta Paediatr. 2006;95(12):1657–60. DOI: 10.1080/08035250600771466
14. Goday-Arno A., Cerda-Esteva M., Flores-Le-Roux J.A., Chillaron-Jordan J.J. et al. Hyperthyroidism in a population with Down syndrome (DS). Clin. Endocrinol. 2009;71(1):110–14. DOI: 10.1111/j.1365-2265.2008.03419.x
15. Nurcan Cebeci A., Schempp V., Förtsch K., Gohlke B. et al. Graves' disease in children with Down syndrome. Endocr. Connect. 2024;13(6):e240032. DOI: 10.1530/EC-24-0032
16. Hershkovitz E., Strich D. Editorial: endocrine dysfunction in patients with Down syndrome. Front. Endocrinol. 2023;14:1336637. DOI: 10.3389/fendo.2023.1336637
17. Dalrymple R.A. Thyroid disorder in children and young people with Down syndrome: DSMIG guideline review. Arch. Dis. Child Eduс. Pract. Ed. 2022;107(1):34–5. DOI: 10.1136/archdischild-2020-321080
18. Erlichman I., Mimouni F.B., Erlichman M., Schimmel M.S. Thyroxine-based screening for congenital hypothyroidism in neonates with Down syndrome. J. Pediatr. 2016;173:165–8. DOI: 10.1016/j.jpeds.2016.02.039
19. Charleton P.M., Dennis J., Marder E. Medical management of children with Down syndrome. Pediatr. Child Health. 2014;24(8):362–9. DOI: 10.1016/j.paed.2013.12.004
20. Gorini F., Coi A., Pierini A., Assanta N. et al. Hypothyroidism in patients with Down syndrome: prevalence and association with congenital heart defects. Children (Basel, Switzerland). 2024;11(5):513. DOI: 10.3390/children11050513
21. Murillo-Llorente M.T., Pérez-Bermejo M., Llacer-Heredia V., Tomás-Aguirre B. et al. Is there an adequate therapeutic approach to thyroid pathology in patients with Down syndrome? Diagnostics (Basel, Switzerland). 2023;13(23):3499. DOI: 10.3390/diagnostics13233499
22. Nagasaki K., Minamitani K., Nakamura A., Kobayashi H. et al. Guidelines for newborn screening of congenital hypothyroidism (2021 revision). Clin. Pediatr. Endocrinol. 2023;32(1):26–51. DOI: 10.1297/cpe.2022-0063
23. Aversa T., Valenzise M., Salerno M., Corrias A. et al. Metamorphic thyroid autoimmunity in Down syndrome: from Hashimoto's thyroiditis to Graves' disease and beyond. Ital. J. Pediatr. 2015;41:87. DOI: 10.1186/s13052-015-0197-4
Review
For citations:
Gudis A.D., Vitebskaya A.V. Features of Thyroid Pathology in Patients with Down Syndrome. Title. 2024;23(6):77-80. (In Russ.) https://doi.org/10.31550/1727-2378-2024-23-6-77-80
Views:
13
Email this article 